Cipla Ltd reported a robust 30% YoY increase in consolidated net profit, reaching Rs 1,222 crore for Q4 FY25, driven by strong sales in India, the US, and Africa. For the full fiscal year, net ...

Updated - March 22, 2025 at 07:16 PM. Cipla is facing moderate headwinds at the moment.

Taiwan-based Formosa Pharmaceuticals (6838.TW) today announced an exclusive licensing agreement with Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as "Cipla" for the commercialization of ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

Hence, submission of Form-Il is not applicable in this case. Cipla has submitted Form-V with NPPA in respect of revised PTR of "Acivir 800 mg Tablet DT 5's" at Rs.175.88 on 03.08.2022. The PTR of the ...

Cipla share price: Cipla Ltd shares fell the most in terms of percentage among all the 50 companies in the NSE Nifty today on Wednesday, October 30, 2024. Cipla share price: Cipla Ltd shares fell ...

Cipla Limited is one of the most famous companies in India which operates in the sphere of healthcare and pharmacology; the company is the pioneer of progressive approaches to the effective treatment ...

Revenue: INR 7,051 crores, growth of 9% year-on-year. EBITDA Margin: 26.7%, highest ever quarterly margin for Cipla. Gross Margin: 67.6%, up 159 basis points from last year. Profit After Tax: INR ...

Cipla anticipates a mid-FY26 launch for Advair, while Abraxane’s release hinges on regulatory approval for the drugmaker's Goa facility, slated as the drug’s manufacturing site.

Cipla reported a consolidated net profit of 13.03 billion rupees ($155 million) for the quarter ended Sept. 30, beating analysts' estimate of 12.34 billion rupees, as per data compiled by LSEG.

Stocks To Watch: UltraTech Cement, Paytm, Power Grid, Cipla, ICICI Bank Stocks to watch today: GIFT Nifty was up 9 points or 0.04% at 24,960 indicating a flat start for domestic indices.

In FY24, Cipla’s revenues exceeded INR 25,000 Cr, and operating margins improved, crossing INR 6,000 Cr for the first time.